A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...
Zacks.com on MSN10d
LLY Falls Around 14% in 3 Months: How to Play the StockEli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
Since 2020, Lilly has committed more than $23 billion for manufacturing capacity for Zepbound and Mounjaro in the United States and Europe. Last week, the FDA removed Mounjaro and Zepbound from ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Novo’s shares fell as much as 27% after the results were announced, hitting their lowest since August 2023 in one of the biggest one-day wipeouts on record for a European company. The stock’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback